

**Enterprise P&T Meeting
Committee Meeting Minutes
April 29, 2024**

Voting Members Present

David Batluck, DO	Rogers Elebra, PharmD	Kelly Martin, PharmD	Jena Quinn, PharmD
Floyd (John) Brinley, MD	Fury Fecondo, PharmD	Michelle Murphy, PharmD	Christy Skibicki, MD
Kirt Caton, MD	Robert Hockmuth, MD	Eric Peters, PharmD	Loretta Sonnier, MD
Robert Clifford, MD	Emily Kryger, PharmD	Andrew Peterson, PharmD	Wayne Weart, PharmD
Donald Cooper, PharmD	Lenaye Lawyer, MD	David Petkash, MD	Rani Whitfield, MD

Excused Voting Members

Tracey Davis, PharmD	Yavar Moghimi, MD
Kendra Michael, MD	Kirby Smith, MD

Invited Guests Present

Christian Andreaggi, PharmD	Rajneel Farley, PharmD	Melissa Megrdochian, PharmD	Ally Seitz, PharmD
Bethany Baird, CPhT	Amanda Hunter, PharmD	Christopher Meny, RPh	Ruth Smith, PharmD
Linda Carreras, CPhT	Toks Kassim, PharmD	Patty Oaster	Mali Thomas, CPhT
Kathleen Clement	Jeffrey Kreitman, PharmD	Sarah Pawlak, PharmD	Lauren Washington, CPhT
Mike Colvin, PharmD	Natasha McGowan	Jeanine Plante, PharmD	Erich Weiss, PharmD
Patrick DeHoratius, PharmD	Lauren Megargell, PharmD	Alishia Richie, MD	Arlene Wiseman, PharmD

Issue	Discussion	Conclusion/Results	Action/ Person Responsible
1. Call to Order	<p>The meeting was called to order at 6:02 PM EST.</p> <p>Welcomed all external and internal participants.</p>	Informational Only	Lenaye Lawyer
2. Conflict of Interest Disclosure	No conflicts announced	Informational Only	Jeffrey Kreitman
3. [REDACTED]		[REDACTED]	[REDACTED]
4. Review and approval of Feb. P&T and March Proxy Minutes		Informational Only	Jeffrey Kreitman
5. Old Business			
Relyvrio	<p>PerformRx makes the following recommendations:</p> <ul style="list-style-type: none"> [REDACTED] [REDACTED] [REDACTED] [REDACTED] <ul style="list-style-type: none"> [REDACTED] [REDACTED] [REDACTED] [REDACTED] 	<p>Committee approved as recommended:</p> <p>Motion: Kirt Caton Second: Robert Hockmuth</p>	<p>PerformRx will update the criteria and formulary/PDL with any changes</p>

	<ul style="list-style-type: none">█ [REDACTED] <p>KF/AHC/█:</p> <ul style="list-style-type: none">Retire the Relyvrio prior authorization criteria as the manufacturer is withdrawing Relyvrio from the market. <p>█</p> <ul style="list-style-type: none">█ [REDACTED]		
█			
█ █ █	█ █	█ █ █ █	█ █ █ █
█ █	█ █ █	█ █ █	█ █ █ █

	<p>[REDACTED]</p>		
<p>[REDACTED]</p>	<p>[REDACTED]</p> <ul style="list-style-type: none">[REDACTED]	<p>[REDACTED]</p>	<p>[REDACTED]</p>
<p>[REDACTED]</p>	<p>[REDACTED]</p> <ul style="list-style-type: none">[REDACTED]	<p>[REDACTED]</p>	<p>[REDACTED]</p>
<p>[REDACTED]</p>	<p>[REDACTED]</p> <ul style="list-style-type: none">[REDACTED][REDACTED]	<p>[REDACTED]</p>	<p>[REDACTED]</p>
<p>6. New Business</p>			

Aduhelm

PerformRx makes the following recommendations:

[REDACTED]
[REDACTED]
[REDACTED]
[REDACTED]

[REDACTED]
[REDACTED]
[REDACTED]
[REDACTED]

[REDACTED]
[REDACTED]
[REDACTED]
[REDACTED]

[REDACTED]
[REDACTED]
[REDACTED]
[REDACTED]

[REDACTED]
[REDACTED]
[REDACTED]
[REDACTED]

KF/AHC [REDACTED]:

Committee approved as recommended:

Motion: Kirt Caton
Second: Robert Hockmuth

PerformRx will update the criteria and formulary/PDL with any changes

	<ul style="list-style-type: none"> Retire the Aduhelm prior authorization criteria as the manufacturer is halting sales and development of Aduhelm. <p>[REDACTED]</p> <ul style="list-style-type: none"> [REDACTED] [REDACTED] [REDACTED] 		
Leqembi	<p>PerformRx makes the following recommendations:</p> <p>[REDACTED]</p> <ul style="list-style-type: none"> [REDACTED] [REDACTED] <p>[REDACTED]</p> <ul style="list-style-type: none"> [REDACTED] [REDACTED] <p>[REDACTED]</p> <ul style="list-style-type: none"> [REDACTED] [REDACTED] <p>[REDACTED]</p> <ul style="list-style-type: none"> [REDACTED] [REDACTED] <p>[REDACTED]</p>	<p>Committee approved as recommended:</p> <p>Motion: Kirt Caton Second: Robert Hockmuth</p> <p>Comment: David Petkash made remarks on Leqembi – how much use are we seeing and are neurologists prescribing? Medicaid has minimal use of Leqembi through Pharmacy. Jeff stated will circle back with additional information.</p>	<p>PerformRx will update the criteria and formulary/PDL with any changes</p>

	<ul style="list-style-type: none"> ■ [REDACTED] ■ [REDACTED] ■ [REDACTED] <p>■ [REDACTED]</p> <ul style="list-style-type: none"> ■ [REDACTED] ■ [REDACTED] ■ [REDACTED] <p>KF/AHC/[REDACTED]:</p> <ul style="list-style-type: none"> • Remove the requirement that approvals must be done by a Medical Director. • Streamline coverage duration section. <p>■ [REDACTED]</p> <ul style="list-style-type: none"> ■ [REDACTED] ■ [REDACTED] ■ [REDACTED] 		
Myasthenia Gravis	<p>PerformRx makes the following recommendations:</p> <p>■ [REDACTED]</p> <ul style="list-style-type: none"> ■ [REDACTED] ■ [REDACTED] ■ [REDACTED] ■ [REDACTED] <p>■ [REDACTED]</p>	<p>Committee approved as recommended:</p> <p>Motion: Kirt Caton Second: Robert Hockmuth</p>	<p>PerformRx will update the criteria and formulary/PDL with any changes</p>

█ [REDACTED]
█ [REDACTED]
█ [REDACTED]

█ [REDACTED]

█ [REDACTED]
█ [REDACTED]
█ [REDACTED]
█ [REDACTED]
█ [REDACTED]

█ [REDACTED]

█ [REDACTED]
█ [REDACTED]
█ [REDACTED]
█ [REDACTED]
█ [REDACTED]

█ [REDACTED]

█ [REDACTED]
█ [REDACTED]
█ [REDACTED]
█ [REDACTED]
█ [REDACTED]

KF/AHC/█:

- Add newly approved Zilbrysq to the drug list and criteria.
- Streamline language regarding requirements for meningococcal vaccinations.

█ [REDACTED]

	<ul style="list-style-type: none">█ [REDACTED]█ [REDACTED]		
Transthyretin-mediated Amyloidosis Agents	<p>PerformRx makes the following recommendations:</p> <p>█ [REDACTED]</p> <ul style="list-style-type: none">█ [REDACTED]█ [REDACTED] <p>█ [REDACTED]</p> <ul style="list-style-type: none">█ [REDACTED] <p>█ [REDACTED]</p> <ul style="list-style-type: none">█ [REDACTED]█ [REDACTED] <p>█ [REDACTED]</p> <ul style="list-style-type: none">█ [REDACTED]	<p>Committee approved as recommended:</p> <p>Motion: Kirt Caton Second: Robert Hockmuth</p>	<p>PerformRx will update the criteria and formulary/PDL with any changes</p>

[REDACTED]

- [REDACTED]
[REDACTED]
[REDACTED]
- [REDACTED]
[REDACTED]

[REDACTED]

- [REDACTED]
[REDACTED]
[REDACTED]
- [REDACTED]
[REDACTED]

KF/AHC/[REDACTED]:

- Add newly approved Wainua to the drug list and criteria as a preferred agent.
- Remove the genetic test requirement for Vyndaqel and Vyndamax.

[REDACTED]

- [REDACTED]
[REDACTED]
[REDACTED]
- [REDACTED]
[REDACTED]

<p>[REDACTED]</p>	<p>[REDACTED]</p>	<p>[REDACTED]</p>	<p>[REDACTED]</p>
<p>[REDACTED]</p>	<p>[REDACTED]</p>	<p>[REDACTED]</p>	<p>[REDACTED]</p>
<p>7. Drug Reviews</p>			
<p>A. Therapeutic Class</p>			
<p>[REDACTED]</p>	<p>[REDACTED]</p>	<p>[REDACTED]</p>	<p>[REDACTED]</p>

	<p>[REDACTED]</p> <ul style="list-style-type: none">[REDACTED]		
B. Single Products			
Provenge with PA Criteria	<p>PerformRx makes the following recommendations:</p> <p>[REDACTED]</p> <ul style="list-style-type: none">[REDACTED][REDACTED] <p>[REDACTED]</p> <ul style="list-style-type: none">[REDACTED] <p>[REDACTED]</p> <ul style="list-style-type: none">[REDACTED][REDACTED] <p>[REDACTED]</p>	<p>Committee approved as recommended:</p> <p>Motion: Alishia Richie Second: Robert Hockmuth</p>	<p>PerformRx will update the criteria and formulary/PDL with any changes</p>

	<ul style="list-style-type: none"> ■ [REDACTED] [REDACTED] [REDACTED] <p>[REDACTED]</p> <ul style="list-style-type: none"> ■ [REDACTED] [REDACTED] ■ [REDACTED] [REDACTED] [REDACTED] <p>KF/AHC/CHC:</p> <ul style="list-style-type: none"> • No changes to the formulary status of Proveng® (sipuleucel-T). • Approve the Dendritic Cell Tumor Peptide Immunotherapy prior authorization with no clinical changes. <p>[REDACTED]</p> <ul style="list-style-type: none"> ■ [REDACTED] [REDACTED] ■ [REDACTED] [REDACTED] [REDACTED] 		
Ridaura	<p>PerformRx makes the following recommendations:</p> <p>[REDACTED]</p> <ul style="list-style-type: none"> ■ [REDACTED] [REDACTED] <p>[REDACTED]</p>	<p>Committee approved as recommended:</p> <p>Motion: Alishia Richie Second: Robert Hockmuth</p>	No Changes

	<ul style="list-style-type: none"> ■ [REDACTED] <p>[REDACTED]</p> <ul style="list-style-type: none"> ■ [REDACTED] <p>KF/AHC/CHC:</p> <ul style="list-style-type: none"> • No change to the formulary status of Ridaura (auranofin). <p>[REDACTED]</p> <ul style="list-style-type: none"> ■ [REDACTED] 		
Filsuvez with PA Criteria	<p>PerformRx makes the following recommendations:</p> <p>[REDACTED]</p> <ul style="list-style-type: none"> ■ [REDACTED] <ul style="list-style-type: none"> ■ [REDACTED] <ul style="list-style-type: none"> ■ [REDACTED] <ul style="list-style-type: none"> ■ [REDACTED] 	<p>Committee approved as recommended:</p> <p>Motion: Alishia Richie Second: Robert Hockmuth</p>	<p>PerformRx will update the criteria and formulary/PDL with any changes</p>

- [REDACTED]
- [REDACTED]
- [REDACTED]
- [REDACTED]
- [REDACTED]

KF/AHC/[REDACTED]:

- Add Filsuvez (birch triterpenes) to Tier 4 with a prior authorization requirement.
- Update the Vyjuvek (beremagene geperpavec-svdt) prior authorization criteria.
- Update title from Vyjuvek (beremagene geperpavec-svdt) to Epidermolysis Bullosa Agents.
- Add Filsuvez (birch triterpenes) to the drug list.
- Update initial coverage duration period to 2 months to align with wound closure assessment timepoints in the clinical trials.
- Update indication information to align with both listed products.
- Add product specific maximum dosing information to the initial and re-authorization criteria.

- [REDACTED]
- [REDACTED]
- [REDACTED]

	<ul style="list-style-type: none"> ■ [REDACTED] ■ [REDACTED] ■ [REDACTED] ■ [REDACTED] ■ [REDACTED] ■ [REDACTED] ■ [REDACTED] ■ [REDACTED] ■ [REDACTED] ■ [REDACTED] 		
<p>Rezdiffra with PA Criteria</p>	<p>PerformRx makes the following recommendations:</p> <p>KF/AHC [REDACTED]:</p> <ul style="list-style-type: none"> • Add Rezdiffra to Tier 4 of the formulary with a prior authorization requirement. • Approve the newly developed Rezdiffra prior authorization criteria. <p>[REDACTED]</p> <ul style="list-style-type: none"> ■ [REDACTED] ■ [REDACTED] 	<p>Committee approved as recommended:</p> <p>Motion: Alishia Richie Second: Robert Hockmuth</p> <p>Comment: Wayne Weart stated that Rezdiffra was approved based on only a 12month study. It was an accelerated approval and not a full approval by the FDA. The other class of drugs are being studied. PerformRx will be monitoring and bring any new developments.</p>	<p>PerformRx will update the criteria and formulary/PDL with any changes</p>

	<p>[REDACTED]</p> <ul style="list-style-type: none"> ■ [REDACTED] ■ [REDACTED] <p>[REDACTED]</p> <ul style="list-style-type: none"> ■ [REDACTED] ■ [REDACTED] <p>[REDACTED]</p> <ul style="list-style-type: none"> ■ [REDACTED] ■ [REDACTED] <p>[REDACTED]</p> <ul style="list-style-type: none"> ■ [REDACTED] ■ [REDACTED] 		
<p>Amtagvi with PA Criteria.</p>	<p>PerformRx makes the following recommendations:</p> <p>[REDACTED]</p> <ul style="list-style-type: none"> ■ [REDACTED] ■ [REDACTED] 	<p>Committee approved as recommended:</p> <p>Motion: Alishia Richie Second: Robert Hockmuth</p>	<p>PerformRx will update the criteria and formulary/PDL with any changes</p>

[REDACTED]
[REDACTED]

[REDACTED]
[REDACTED]
[REDACTED]

[REDACTED]
[REDACTED]

[REDACTED]
[REDACTED]
[REDACTED]

KF/AHC/[REDACTED]:

- Add Amtagvi to Tier 4 with a prior authorization requirement.
- Approve ethe newly developed Amtagvi prior authorization criteria.

[REDACTED]
[REDACTED]
[REDACTED]

<p>Sucraid</p>	<p>PerformRx makes the following recommendations:</p> <p>[REDACTED]</p> <p>[REDACTED]</p> <p>[REDACTED]</p> <p>[REDACTED]</p> <p>KF/AHC/[REDACTED]:</p> <ul style="list-style-type: none"> • No changes to the formulary status of Sucraid (sacrosidase). <p>[REDACTED]</p> <p>[REDACTED]</p>	<p>Committee approved as recommended:</p> <p>Motion: Alishia Richie Second: Robert Hockmuth</p>	<p>No Changes</p>
<p>Adzynma with PA Criteria</p>	<p>PerformRx makes the following recommendations:</p> <p>[REDACTED]</p> <p>[REDACTED]</p> <p>[REDACTED]</p> <p>[REDACTED]</p> <p>[REDACTED]</p>	<p>Committee approved as recommended:</p> <p>Motion: Alishia Richie Second: Robert Hockmuth</p>	<p>PerformRx will update the criteria and formulary/PDL with any changes</p>

- [REDACTED]
[REDACTED]
[REDACTED]
- [REDACTED]
[REDACTED]

- [REDACTED]
- [REDACTED]
[REDACTED]

- [REDACTED]
- [REDACTED]
[REDACTED]

- [REDACTED]
- [REDACTED]
[REDACTED]
 - [REDACTED]
[REDACTED]

- [REDACTED]
- [REDACTED]
[REDACTED]
 - [REDACTED]
[REDACTED]

KF/AHC/[REDACTED]:

- Add Adzynma to Tier 4 with a prior authorization requirement.
- Approve the newly developed Adzynma prior authorization criteria.

[REDACTED]

	<ul style="list-style-type: none">█ [REDACTED]█ [REDACTED]		
Eohilia with PA Criteria.	<p>PerformRx makes the following recommendations:</p> <p>█ [REDACTED]</p> <ul style="list-style-type: none">█ [REDACTED]█ [REDACTED] <p>█ [REDACTED]</p> <ul style="list-style-type: none">█ [REDACTED]█ [REDACTED] <p>█ [REDACTED]</p> <ul style="list-style-type: none">█ [REDACTED]█ [REDACTED] <p>█ [REDACTED]</p> <ul style="list-style-type: none">█ [REDACTED]█ [REDACTED] <p>█ [REDACTED]</p>	<p>Committee approved as recommended:</p> <p>Motion: Alishia Richie Second: Robert Hockmuth</p>	<p>PerformRx will update the criteria and formulary/PDL with any changes</p>

	<p>[REDACTED]</p> <ul style="list-style-type: none">[REDACTED][REDACTED]		
<p>8. New Products</p>	<p>PerformRx makes the following recommendations:</p> <p>[REDACTED]</p> <ul style="list-style-type: none">[REDACTED] <p>[REDACTED]</p> <ul style="list-style-type: none">[REDACTED] <p>[REDACTED]</p> <ul style="list-style-type: none">[REDACTED] <p>Add to the formulary for [REDACTED] KF/AHC/[REDACTED].</p> <ul style="list-style-type: none">• Penbraya <p>[REDACTED]</p> <ul style="list-style-type: none">[REDACTED] <p>[REDACTED]</p> <p>[REDACTED]:</p>	<p>Committee approved as recommended:</p> <p>Motion: Donald Cooper Second: Alishia Richie</p>	<p>PerformRx will update the criteria and formulary/PDL with any changes</p>

Natriuretic Peptides for
Achondroplasia (Voxzogo)

PerformRx makes the following
recommendations:

[REDACTED]
[REDACTED]
[REDACTED]
[REDACTED]
[REDACTED]

[REDACTED]
[REDACTED]
[REDACTED]
[REDACTED]
[REDACTED]

[REDACTED]
[REDACTED]
[REDACTED]
[REDACTED]
[REDACTED]

[REDACTED]
[REDACTED]
[REDACTED]
[REDACTED]
[REDACTED]

[REDACTED]
[REDACTED]
[REDACTED]

Committee approved as
recommended:

Motion: Donald Cooper
Second: Alishia Richie

PerformRx will
update the criteria
and formulary/PDL
with any changes

	<p>[REDACTED] [REDACTED] [REDACTED] [REDACTED]</p> <p>KF/AHC/[REDACTED]:</p> <ul style="list-style-type: none">• Update the language to baseline growth velocity due to the age expansion population not having to meeting a minimum height velocity for inclusion in the trial. <p>[REDACTED]</p> <ul style="list-style-type: none">• [REDACTED] [REDACTED] [REDACTED] [REDACTED] [REDACTED]		
<p>[REDACTED]</p>	<p>[REDACTED] [REDACTED]</p> <p>[REDACTED]</p> <ul style="list-style-type: none">• [REDACTED] [REDACTED] [REDACTED] [REDACTED] <p>[REDACTED]</p> <ul style="list-style-type: none">• [REDACTED] [REDACTED] [REDACTED] [REDACTED] <p>[REDACTED]</p>	<p>[REDACTED] [REDACTED]</p> <p>[REDACTED] [REDACTED]</p>	<p>[REDACTED] [REDACTED] [REDACTED] [REDACTED]</p>

	<ul style="list-style-type: none">█ [REDACTED]█ [REDACTED]█ [REDACTED]█ [REDACTED] <p>[REDACTED]</p> <ul style="list-style-type: none">█ [REDACTED]█ [REDACTED]█ [REDACTED]█ [REDACTED]		
<p>Peanut Allergy Immunotherapy Agents</p>	<p>PerformRx makes the following recommendations:</p> <p>[REDACTED]</p> <ul style="list-style-type: none">█ [REDACTED]█ [REDACTED] <p>[REDACTED]</p> <ul style="list-style-type: none">█ [REDACTED]█ [REDACTED] <p>[REDACTED]</p> <ul style="list-style-type: none">█ [REDACTED]█ [REDACTED] <p>[REDACTED]</p> <ul style="list-style-type: none">█ [REDACTED]█ [REDACTED] <p>KF/AHC/[REDACTED]:</p> <ul style="list-style-type: none">• Exclude the concomitant use of Palforzia and Xolair.	<p>Committee approved as recommended:</p> <p>Motion: Donald Cooper Second: Alishia Richie</p>	<p>PerformRx will update the criteria and formulary/PDL with any changes</p>

	<ul style="list-style-type: none">• Add language for initial and re-authorizations to be approved for all strengths and dosage forms of Palforzia. <p>[Redacted]</p>		
[Redacted]	<p>[Redacted]</p> <p>[Redacted]</p> <p>[Redacted]</p> <p>[Redacted]</p> <p>[Redacted]</p> <p>[Redacted]</p> <p>[Redacted]</p> <p>[Redacted]</p>	<p>[Redacted]</p> <p>[Redacted]</p> <p>[Redacted]</p> <p>[Redacted]</p>	<p>[Redacted]</p> <p>[Redacted]</p> <p>[Redacted]</p> <p>[Redacted]</p>
[Redacted]	<p>[Redacted]</p> <p>[Redacted]</p> <p>[Redacted]</p> <p>[Redacted]</p> <p>[Redacted]</p>	<p>[Redacted]</p> <p>[Redacted]</p> <p>[Redacted]</p> <p>[Redacted]</p>	<p>[Redacted]</p> <p>[Redacted]</p> <p>[Redacted]</p> <p>[Redacted]</p>

	<ul style="list-style-type: none">■ [REDACTED] <p>[REDACTED]</p> <ul style="list-style-type: none">■ [REDACTED]■ [REDACTED]		
Somatostatin Analogs	<p>PerformRx makes the following recommendations:</p> <ul style="list-style-type: none">■ [REDACTED] <p>[REDACTED]</p> <ul style="list-style-type: none">■ [REDACTED] <p>[REDACTED]</p> <ul style="list-style-type: none">■ [REDACTED]	<p>Committee approved as recommended:</p> <p>Motion: Donald Cooper Second: Alishia Richie</p>	<p>PerformRx will update the criteria and formulary/PDL with any changes</p>

	<p>[REDACTED]</p> <ul style="list-style-type: none">[REDACTED] <p>[REDACTED]</p> <ul style="list-style-type: none">[REDACTED] <p>[REDACTED]</p> <ul style="list-style-type: none">[REDACTED] <p>KF/AHC/[REDACTED]:</p> <ul style="list-style-type: none">Approve the Somatostatin Analogs and Growth Hormone Receptor Antagonists prior authorization criteria with no clinical changes. <p>[REDACTED]</p> <ul style="list-style-type: none">[REDACTED]		
<p>[REDACTED]</p>	<p>[REDACTED]</p>	<p>[REDACTED]</p>	<p>[REDACTED]</p>

<p>[REDACTED]</p>	<p>[REDACTED]</p>	<p>[REDACTED]</p>	<p>[REDACTED]</p>
<p>B. Prior Authorization Criteria Annual Review without Clinical Changes:</p>			
<p>Diagnosis Code Requirement</p>	<p>PerformRx makes the following recommendations:</p> <p>[REDACTED]</p> <p>[REDACTED]</p> <p>[REDACTED]</p> <p>[REDACTED]</p> <p>KF/AHC/[REDACTED]:</p> <ul style="list-style-type: none">• Approve the Diagnosis Code Requirement prior authorization criteria with no changes. <p>[REDACTED]</p> <p>[REDACTED]</p> <p>[REDACTED]</p>	<p>Committee approved as recommended:</p> <p>Motion: Donald Cooper Second: Alishia Richie</p>	<p>No Changes</p>

	<ul style="list-style-type: none">■ [REDACTED] <p>[REDACTED]</p> <ul style="list-style-type: none">■ [REDACTED] <p>[REDACTED]</p> <ul style="list-style-type: none">■ [REDACTED]		
Antisense Oligonucleotides for Duchenne Muscular Dystrophy	<p>PerformRx makes the following recommendations:</p> <p>[REDACTED]</p> <ul style="list-style-type: none">■ [REDACTED] <p>[REDACTED]</p> <ul style="list-style-type: none">■ [REDACTED] <p>[REDACTED]</p> <ul style="list-style-type: none">■ [REDACTED]	<p>Committee approved as recommended:</p> <p>Motion: Donald Cooper Second: Alishia Richie</p>	<p>No Changes</p>

	<p>[REDACTED]</p> <p>[REDACTED]</p> <p>[REDACTED]</p> <p>[REDACTED]</p> <p>KF/AHC/[REDACTED]:</p> <ul style="list-style-type: none">• Approve the Atovaquone Suspension prior authorization criteria with no clinical changes. <p>[REDACTED]</p> <p>[REDACTED]</p> <p>[REDACTED]</p>		
<p>[REDACTED]</p> <p>[REDACTED]</p>	<p>[REDACTED]</p> <p>[REDACTED]</p> <p>[REDACTED]</p> <p>[REDACTED]</p> <p>[REDACTED]</p> <p>[REDACTED]</p> <p>[REDACTED]</p> <p>[REDACTED]</p>	<p>[REDACTED]</p> <p>[REDACTED]</p> <p>[REDACTED]</p> <p>[REDACTED]</p>	<p>[REDACTED]</p>

	<p>[REDACTED]</p> <ul style="list-style-type: none">[REDACTED] <p>[REDACTED]</p> <ul style="list-style-type: none">[REDACTED] <p>[REDACTED]</p> <ul style="list-style-type: none">[REDACTED]		
Blincyto	<p>PerformRx makes the following recommendations:</p> <p>[REDACTED]</p> <ul style="list-style-type: none">[REDACTED] <p>[REDACTED]</p> <ul style="list-style-type: none">[REDACTED] <p>[REDACTED]</p> <ul style="list-style-type: none">[REDACTED] <p>[REDACTED]</p>	<p>Committee approved as recommended:</p> <p>Motion: Donald Cooper Second: Alishia Richie</p>	No Changes

	<ul style="list-style-type: none">■ [REDACTED]■ [REDACTED]■ [REDACTED] <p>[REDACTED]</p> <ul style="list-style-type: none">■ [REDACTED]■ [REDACTED]■ [REDACTED] <p>KF/AHC/[REDACTED]:</p> <ul style="list-style-type: none">• Approve the Blincyto prior authorization criteria with no clinical changes. <p>[REDACTED]</p> <ul style="list-style-type: none">■ [REDACTED]■ [REDACTED]■ [REDACTED]		
<p>[REDACTED]</p>	<p>[REDACTED]</p> <p>[REDACTED]</p> <p>[REDACTED]</p> <ul style="list-style-type: none">■ [REDACTED]■ [REDACTED]■ [REDACTED] <p>[REDACTED]</p> <ul style="list-style-type: none">■ [REDACTED]■ [REDACTED]■ [REDACTED] <p>[REDACTED]</p>	<p>[REDACTED]</p> <p>[REDACTED]</p> <p>[REDACTED]</p> <p>[REDACTED]</p>	<p>[REDACTED]</p>

	<ul style="list-style-type: none">█ [REDACTED]		
Filspari	<p>PerformRx makes the following recommendations:</p> <ul style="list-style-type: none">█ [REDACTED]█ [REDACTED]█ [REDACTED]█ [REDACTED]█ [REDACTED]█ [REDACTED]█ [REDACTED] <p>KF/AHC/█:</p> <ul style="list-style-type: none">• Approve the Filspari prior authorization criteria with no clinical changes.	<p>Committee approved as recommended:</p> <p>Motion: Donald Cooper Second: Alishia Richie</p>	No Changes

	<p>[REDACTED]</p> <p>[REDACTED]</p> <p>KF/AHC/[REDACTED]:</p> <ul style="list-style-type: none">• Approve the Hydroxyprogesterone caproate (generic Delalutin) prior authorization criteria with no clinical changes. <p>[REDACTED]</p> <ul style="list-style-type: none">• [REDACTED] <p>[REDACTED]</p>		
<p>[REDACTED]</p> <p>[REDACTED]</p>	<p>[REDACTED]</p> <ul style="list-style-type: none">• [REDACTED] <p>[REDACTED]</p> <ul style="list-style-type: none">• [REDACTED] <p>[REDACTED]</p> <ul style="list-style-type: none">• [REDACTED] <p>[REDACTED]</p>	<p>[REDACTED]</p> <p>[REDACTED]</p> <p>[REDACTED]</p>	<p>[REDACTED]</p>

	<ul style="list-style-type: none"> ■ [REDACTED] [REDACTED] [REDACTED] <ul style="list-style-type: none"> ■ [REDACTED] [REDACTED] [REDACTED] 		
<p>[REDACTED]</p> <p>[REDACTED]</p>	<p>[REDACTED]</p> <p>[REDACTED]</p> <ul style="list-style-type: none"> ■ [REDACTED] [REDACTED] [REDACTED] [REDACTED] <ul style="list-style-type: none"> ■ [REDACTED] [REDACTED] [REDACTED] [REDACTED] <ul style="list-style-type: none"> ■ [REDACTED] [REDACTED] [REDACTED] [REDACTED] 	<p>[REDACTED]</p> <p>[REDACTED]</p> <p>[REDACTED]</p> <p>[REDACTED]</p>	<p>[REDACTED]</p>
<p>Jesduvroq</p>	<p>PerformRx makes the following recommendations:</p> <p>[REDACTED]</p>	<p>Committee approved as recommended:</p> <p>Motion: Donald Cooper</p>	<p>No Changes</p>

Second: Alishia Richie

█ [REDACTED]
█ [REDACTED]
█ [REDACTED]

█ [REDACTED]
█ [REDACTED]
█ [REDACTED]
█ [REDACTED]

█ [REDACTED]
█ [REDACTED]
█ [REDACTED]
█ [REDACTED]

█ [REDACTED]
█ [REDACTED]
█ [REDACTED]
█ [REDACTED]

█ [REDACTED]
█ [REDACTED]
█ [REDACTED]
█ [REDACTED]

KF/AHC/█:
• Approve the Jesduvroq prior authorization criteria with no clinical changes.

█ [REDACTED]
█ [REDACTED]
█ [REDACTED]
█ [REDACTED]

Ketamine

PerformRx makes the following recommendations:

Committee approved as recommended:

No Changes

[REDACTED]
[REDACTED]
[REDACTED]
[REDACTED]

[REDACTED]
[REDACTED]
[REDACTED]
[REDACTED]

[REDACTED]
[REDACTED]
[REDACTED]
[REDACTED]

[REDACTED]
[REDACTED]
[REDACTED]
[REDACTED]

[REDACTED]
[REDACTED]
[REDACTED]
[REDACTED]

- KF/AHC [REDACTED]:**
- Approve the Ketamine prior authorization criteria with no clinical changes.

[REDACTED]

Motion: Donald Cooper
Second: Alishia Richie

	<ul style="list-style-type: none">█ [REDACTED]		
Kuvan	<p>PerformRx makes the following recommendations:</p> <ul style="list-style-type: none">█ [REDACTED]█ [REDACTED]█ [REDACTED]█ [REDACTED]█ [REDACTED]█ [REDACTED] <p>KF/AHC/█:</p> <ul style="list-style-type: none">• Approve the Kuvan prior authorization criteria with no clinical changes. <ul style="list-style-type: none">█ [REDACTED]	<p>Committee approved as recommended:</p> <p>Motion: Donald Cooper Second: Alishia Richie</p>	No Changes
Lamzede	<p>PerformRx makes the following recommendations:</p>	<p>Committee approved as recommended:</p>	

Linezolid (Zyvox)	PerformRx makes the following recommendations:	Committee approved as recommended:	No Changes
<p>[REDACTED]</p> <p>[REDACTED]</p> <p>[REDACTED]</p>	<p>[REDACTED]</p> <ul style="list-style-type: none"> [REDACTED] <p>[REDACTED]</p> <p>KF/AHC/[REDACTED]:</p> <ul style="list-style-type: none"> Approve the linezolid (Zyvox) prior authorization criteria with no clinical changes. <p>[REDACTED]</p> <ul style="list-style-type: none"> [REDACTED] <p>[REDACTED]</p>	<p>Motion: Donald Cooper Second: Alishia Richie</p> <p>[REDACTED]</p> <p>[REDACTED]</p>	<p>[REDACTED]</p>

Palynziq

PerformRx makes the following recommendations:

[REDACTED]
[REDACTED]
[REDACTED]

[REDACTED]
[REDACTED]
[REDACTED]

[REDACTED]
[REDACTED]
[REDACTED]

[REDACTED]
[REDACTED]
[REDACTED]

[REDACTED]
[REDACTED]
[REDACTED]

KF/AHC/[REDACTED]:

- Approve the Palynziq prior authorization criteria with no clinical changes.

[REDACTED]

Committee approved as recommended:

Motion: Donald Cooper
Second: Alishia Richie

No Changes

Primary HLH Agents

PerformRx makes the following recommendations:

Committee approved as recommended:

No Changes

[Redacted]

Motion: Donald Cooper
Second: Alishia Richie

[Redacted]

[Redacted]

[Redacted]

[Redacted]

[Redacted]

	<ul style="list-style-type: none">█ [REDACTED] <p>KF/AHC/█:</p> <ul style="list-style-type: none">• Approve the Primary Hemophagocytic Lymphohistiocytosis (HLH) Agents prior authorization criteria with no clinical changes. <p>█</p> <ul style="list-style-type: none">█ [REDACTED]		
Radicava	<p>PerformRx makes the following recommendations:</p> <p>█</p> <ul style="list-style-type: none">█ [REDACTED] <p>█</p> <ul style="list-style-type: none">█ [REDACTED] <p>█</p>	<p>Committee approved as recommended:</p> <p>Motion: Donald Cooper Second: Alishia Richie</p>	<p>No Changes</p>

	<ul style="list-style-type: none">■ [REDACTED]■ [REDACTED]■ [REDACTED] <p>[REDACTED]</p> <ul style="list-style-type: none">■ [REDACTED]■ [REDACTED]■ [REDACTED] <p>[REDACTED]</p> <ul style="list-style-type: none">■ [REDACTED]■ [REDACTED]■ [REDACTED] <p>[REDACTED]</p> <ul style="list-style-type: none">■ [REDACTED]■ [REDACTED]■ [REDACTED] <p>KF/AHC/[REDACTED]:</p> <ul style="list-style-type: none">• Approve the Radicava prior authorization criteria with no clinical changes. <p>[REDACTED]</p> <ul style="list-style-type: none">■ [REDACTED]■ [REDACTED]■ [REDACTED]		
[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]

	<ul style="list-style-type: none">■ [REDACTED]■ [REDACTED]■ [REDACTED] <ul style="list-style-type: none">■ [REDACTED]■ [REDACTED]■ [REDACTED]		
Topical mTOR Kinase Inhibitors	<p>PerformRx makes the following recommendations:</p> <ul style="list-style-type: none">■ [REDACTED]■ [REDACTED]■ [REDACTED] <ul style="list-style-type: none">■ [REDACTED]■ [REDACTED]■ [REDACTED] <ul style="list-style-type: none">■ [REDACTED]■ [REDACTED]■ [REDACTED] <p>KF/AHC/ [REDACTED]:</p> <ul style="list-style-type: none">• Approve the Topical mTOR Kinase Inhibitors prior authorization criteria with no clinical changes.	<p>Committee approved as recommended:</p> <p>Motion: Donald Cooper Second: Alishia Richie</p>	<p>No Changes</p>

	<p>[REDACTED]</p> <p>[REDACTED]</p> <p>KF/AHC/[REDACTED]:</p> <ul style="list-style-type: none">• Approve the Treatments for Plasminogen Deficiency Type 1 (PLD1) prior authorization criteria with no clinical changes.• [REDACTED] <p>[REDACTED]</p> <ul style="list-style-type: none">• [REDACTED] <p>[REDACTED]</p>		
<p>[REDACTED]</p> <p>[REDACTED]</p>	<p>[REDACTED]</p> <p>[REDACTED]</p> <p>[REDACTED]</p> <ul style="list-style-type: none">• [REDACTED] <p>[REDACTED]</p> <ul style="list-style-type: none">• [REDACTED] <p>[REDACTED]</p>	<p>[REDACTED]</p> <p>[REDACTED]</p> <p>[REDACTED]</p> <p>[REDACTED]</p>	<p>[REDACTED]</p>
<p>[REDACTED]</p>	<p>[REDACTED]</p> <p>[REDACTED]</p> <p>[REDACTED]</p> <ul style="list-style-type: none">• [REDACTED] <p>[REDACTED]</p> <ul style="list-style-type: none">• [REDACTED] <p>[REDACTED]</p>	<p>[REDACTED]</p> <p>[REDACTED]</p> <p>[REDACTED]</p> <p>[REDACTED]</p>	<p>[REDACTED]</p>
<p>[REDACTED]</p> <p>[REDACTED]</p>	<p>[REDACTED]</p> <p>[REDACTED]</p>	<p>[REDACTED]</p> <p>[REDACTED]</p>	<p>[REDACTED]</p>

	<p>[REDACTED]</p> <p>[REDACTED]</p> <p>[REDACTED]</p> <p>[REDACTED]</p>	<p>[REDACTED]</p> <p>[REDACTED]</p>	
10. Recalls	<p>1/30/2024 – 4/17/2024</p> <p>There were no Class 1 or 2 recalls impacting all lots for medications listed within Medispan.</p>	Informational	PerformRx
11. Adjournment	The meeting adjourned at 7:07 PM EST		Lenaye Lawyer
	The next meeting July 29th, 2024 6:00pm- 8:00pm EST		

Jeffrey Phillip Pham

7/29/24
Date